Eli Lilly (LLY) Prepaid Assets (2009 - 2026)
Eli Lilly (LLY) reported Prepaid Assets of $214.0 million for Q1 2026, down 98.54% on a YoY basis from $14.7 billion in Q1 2025, and down 98.51% quarter-over-quarter from $14.3 billion in Q4 2025.
Eli Lilly (LLY) Prepaid Assets (2009 - 2026) Analysis & Trends
Eli Lilly has reported Prepaid Assets for 18 years, with the latest figure at $214.0 million in Q1 2026.
- For the quarter ending Q1 2026, Prepaid Assets fell 98.54% year-over-year to $214.0 million; the trailing twelve-month figure through Mar 2026 stood at $214.0 million (down 98.54% YoY), and the FY2025 full-year result was $14.3 billion, up 5281.58% from the prior year.
- Prepaid Assets for Q1 2026 stood at $214.0 million, down from $14.3 billion in the prior quarter.
- The five-year high for Prepaid Assets was $20.2 billion in Q3 2025, with the low at $7.3 million in Q4 2022.
- Historically, Prepaid Assets has averaged $4.6 billion across 5 years, with a median of $2.7 billion in 2022.
- Annual changes were most pronounced in 2022 — Prepaid Assets tumbled 99.71% — and 2025, when it soared 14943.61%.
- Eli Lilly's Prepaid Assets stood at $7.3 million in 2022, then soared by 1947.95% to $149.5 million in 2023, then jumped by 77.93% to $266.0 million in 2024, then jumped by 5281.58% to $14.3 billion in 2025, then slumped by 98.51% to $214.0 million in 2026.
- The last three Prepaid Assets figures came in at $214.0 million (Q1 2026), $14.3 billion (Q4 2025), and $20.2 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 214.00 Mn |
| Dec 31, 2025 | 14.32 Bn |
| Sep 30, 2025 | 20.25 Bn |
| Jun 30, 2025 | 68.80 Mn |
| Mar 31, 2025 | 14.65 Bn |
| Dec 31, 2024 | 266.00 Mn |
| Sep 30, 2024 | 134.60 Mn |
| Jun 30, 2024 | 142.20 Mn |
| Mar 31, 2024 | 6.35 Bn |
| Dec 31, 2023 | 149.50 Mn |
| Sep 30, 2023 | 5.25 Bn |
| Jun 30, 2023 | 4.53 Bn |
| Mar 31, 2023 | 3.58 Bn |
| Dec 31, 2022 | 7.30 Mn |
| Sep 30, 2022 | 2.74 Bn |
| Jun 30, 2022 | 2.81 Bn |
| Mar 31, 2022 | 2.70 Bn |
| Dec 31, 2021 | 2.53 Bn |
| Sep 30, 2021 | 3.05 Bn |
| Jun 30, 2021 | 3.30 Bn |